公开(公告)号：EP2705853B1

公开(公告)日：2018-07-18

申请号：EP11865292.4

申请日：2011-05-06

申请人： Aparin, Petr Gennadievich ,  Lvov, Vyacheslav Leonidovich

发明人： ELKINA, Stanislava Ivanovna ,  GOLOVINA, Marina Eduardovna ,  SHMIGOL, Vladimir Igorevich

IPC分类号： A61K39/112 ,  A61P37/02 ,  C12N1/00 ,  C12P19/26 ,  C08B37/00 ,  C08L5/00

CPC分类号： C08B37/006 ,  A61K39/0283 ,  A61K2039/58 ,  A61K2039/6037 ,  C08B37/0003 ,  C08L5/00 ,  C12N2760/16121 ,  C12P19/26 ,  Y02A50/476

摘要： For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide consisting of 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2,4-dideoxy-²-D-galactopyranosyl]-(1†’4)-O-[2-(N-acetyl)amino-2-deoxy-±-L-altrpyranuronic acid] linked by (1†’3) bonds to form a polysaccharide chain. The exopolysaccharide has a molecular mass of from 0.4 to 400 kDa, contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity, generating mucosal protection against Shigella sonnei shigellosis by inducing the synthesis of specific antibodies against S. sonnei in mammals, including humans. Without using lipopolysaccharides as the source of production, an exopolysaccharide with a high degree of purity is produced from a liquid phase culture of S. sonnei bacteria by means of a workable industrial method with a high yield. Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.

公开(公告)号：EP2240570B1

公开(公告)日：2013-12-11

申请号：EP09702047.3

申请日：2009-01-16

申请人： Lubitz, Werner

发明人： Lubitz, Werner

IPC分类号： C12N1/06 ,  A61K39/108 ,  A61K39/112 ,  A61K35/74

CPC分类号： A61K39/0258 ,  A61K39/0283 ,  A61K2039/521 ,  A61K2039/55594 ,  C12N1/06 ,  Y02A50/474 ,  Y02A50/476

摘要： The invention relates to bacterial ghost preparation using betapropiolactone for final inactivation of bacteria.

公开(公告)号：EP2657251A1

公开(公告)日：2013-10-30

申请号：EP13176694.1

申请日：2005-05-24

申请人： The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： Xu, DeQi ,  Kopecko, Dennis, J.

IPC分类号： C07K14/25 ,  A61K39/112 ,  C12N15/52

CPC分类号： A61K39/0283 ,  A61K48/00 ,  A61K2039/522 ,  A61K2039/523 ,  C07K14/25 ,  C12N15/52 ,  Y02A50/484

摘要： The invention relates to an expression vector comprising a core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2; b) DNA encoding S. dysenteriae serotype 1 biosynthesis polypeptides encoded by any one of SEQ ID NOs: 1 and 2; c) DNA encoding variants of the polypeptide encoded by the DNA of (a) or (b), wherein the variants comprise O antigen biosynthesis polypeptide analogs, wherein one or more of the specified amino acids is deleted or replaced, or wherein one or more non-specified amino acids are added without loss of biosynthesis of Shigella dysenteriae serotype 1 O antigen or protective immunological activity of the O antigen biosynthesis gene product; and d) nucleic acid molecules encoding gene products that share at least about 90% sequence identity with the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 2.

摘要翻译： 本发明涉及包含核心型痢疾志贺氏族血清型O特异性多糖（O-Ps）和编码O抗原生物合成的DNA的表达载体，所述DNA选自：a）任何 SEQ ID NO：1和2之一; b）编码由SEQ ID NO：1和2中任一个编码的痢疾肠炎血清型1生物合成多肽的DNA; c）编码由（a）或（b）的DNA编码的多肽的变体的DNA，其中所述变体包含O抗原生物合成多肽类似物，其中一个或多个特定氨基酸被缺失或替换，或其中一个或多个 添加非特异氨基酸，而不损失痢疾志贺氏菌血清型1 O抗原的生物合成或O抗原生物合成基因产物的保护性免疫活性; 和d）编码与由SEQ ID NO：1或2的核酸分子编码的多肽共有至少约90％序列同一性的基因产物的核酸分子。

公开(公告)号：EP2150274B1

公开(公告)日：2013-08-21

申请号：EP08743288.6

申请日：2008-04-25

申请人： The United States Of America As Represented By The Secretary of the Army

发明人： VENKATESAN, Malabi M. ,  RANALLO, Ryan T. ,  BARNOY, Shoshana

IPC分类号： A61K39/02

CPC分类号： A61K39/0283 ,  A61K2039/522 ,  Y02A50/476

摘要： Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (&Dgr;senA, &Dgr;senB, &Dgr;virG, &Dgr;msbB2), WRSf2G15 (&Dgr;virG, &Dgr;setAB, &Dgr;senA, &Dgr;senB, &Dgr;msbB2), and WRSd5 (&Dgr;virG, &Dgr;stxAB, &Dgr;senA, &Dgr;senB, &Dgr;msbB2).

公开(公告)号：EP2501406A4

公开(公告)日：2013-04-24

申请号：EP10831896

申请日：2010-11-16

申请人： GLYCOVAXYN AG

发明人： WACKER MICHAEL ,  WAECHTER CHARLES

IPC分类号： A61K39/385 ,  A61K39/02 ,  A61K39/108 ,  C07K1/00

CPC分类号： A61K39/0258 ,  A61K39/0283 ,  A61K39/385 ,  A61K47/646 ,  A61K2039/6068

摘要： The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.

摘要翻译： 本发明涉及包含N-糖基化蛋白质的生物缀合物疫苗。 此外，本发明涉及包含编码差向异构酶的核酸的重组原核生物合成系统，所述差向异构酶在还原末端合成具有N-乙酰半乳糖胺的寡糖或多糖。 本发明还涉及含有在还原末端具有N-乙酰半乳糖胺的寡糖或多糖的N-糖基化蛋白质和表达系统以及用于制备这种N-糖基化蛋白质的方法。

公开(公告)号：EP2546260A1

公开(公告)日：2013-01-16

申请号：EP12186545.5

申请日：2005-05-24

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Kopecko, Dennis, J. ,  Xu, DeQi

IPC分类号： C07K14/25 ,  A61K39/112 ,  C12N15/52

CPC分类号： A61K39/0283 ,  A61K48/00 ,  A61K2039/522 ,  A61K2039/523 ,  C07K14/25 ,  C12N15/52 ,  Y02A50/484

摘要： The present invention relates to Salmonella typhi Ty21a a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2; b) DNA encoding S. dysenteriae serotype 1 biosynthesis polypeptides encoded by any one of SEQ ID NOs: 1 and 2; c) DNA encoding variants of the polypeptide encoded by the DNA of (a) or (b), wherein the variants comprise O antigen biosynthesis polypeptide analogs, wherein one or more of the specified amino acids is deleted or replaced, or wherein one or more non-specified amino acids are added without loss of biosynthesis of Shigella dysenteriae serotype 1 O antigen or protective immunological activity of the O antigen biosynthesis gene product; and d) nucleic acid molecules encoding gene products that share at least about 90% sequence identity with the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 2.

摘要翻译： 本发明涉及包含核心型痢疾志贺氏菌I型O特异性多糖（O-Ps）和编码O抗原生物合成的DNA的伤寒沙门氏菌Ty21aa，所述DNA选自：a） SEQ ID NO：1和2中的任一个; b）编码由SEQ ID NO：1和2中任一个编码的痢疾肠炎血清型1生物合成多肽的DNA; c）编码由（a）或（b）的DNA编码的多肽的变体的DNA，其中所述变体包含O抗原生物合成多肽类似物，其中一个或多个特定氨基酸被缺失或替换，或其中一个或多个 添加非特异氨基酸，而不损失痢疾志贺氏菌血清型1 O抗原的生物合成或O抗原生物合成基因产物的保护性免疫活性; 和d）编码与由SEQ ID NO：1或2的核酸分子编码的多肽共有至少约90％序列同一性的基因产物的核酸分子。

公开(公告)号：EP2475393A2

公开(公告)日：2012-07-18

申请号：EP10816242.1

申请日：2010-09-13

申请人： Truong-Le, Vu ,  Ohtake, Satoshi ,  Chiueh, Gary ,  Martin, Russell ,  Saxena, Atul ,  Pham, Binh ,  Lechuga-Ballesteros, David

发明人： Truong-Le, Vu ,  Ohtake, Satoshi ,  Chiueh, Gary ,  Martin, Russell ,  Saxena, Atul ,  Pham, Binh ,  Lechuga-Ballesteros, David

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K39/12 ,  A61K39/02 ,  A61K39/085 ,  A61K39/09 ,  A61K39/112 ,  A61K39/108 ,  A61K39/04 ,  A61K39/104 ,  A61K39/07 ,  A61P37/04

CPC分类号： A61K39/07 ,  A61K39/0208 ,  A61K39/0275 ,  A61K39/0283 ,  A61K39/12 ,  A61K39/165 ,  A61K47/183 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/5254 ,  A61K2039/55505 ,  A61K2039/55561 ,  C12N7/00 ,  C12N2760/18411 ,  C12N2760/18434 ,  C12N2760/18451 ,  Y02A50/476 ,  Y02A50/482

摘要： This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vaccines at room temperature.

公开(公告)号：EP2342217A4

公开(公告)日：2012-04-04

申请号：EP09821664

申请日：2009-10-21

申请人： INTERNAT VACCINE INST

发明人： CZERKINSKY CECIL ,  KIM DONG WOOK

IPC分类号： C07K14/25 ,  C12N15/31 ,  C12N15/63

CPC分类号： C07K14/25 ,  A61K39/0283 ,  A61K2039/55566 ,  A61K2039/6037 ,  A61K2039/6087

摘要： The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.

公开(公告)号：EP2369345A1

公开(公告)日：2011-09-28

申请号：EP10011475.0

申请日：2004-07-02

申请人： Institut Pasteur ,  INSERM - Institut National de la Santé et de la Recherche Médicale ,  Centre National De La Recherche Scientifique CNRS

发明人： Phalipon, Armelle ,  Nato, Farida ,  Mulard, Laurence ,  Sansonetti, Philippe ,  Baleux, Francoise ,  Belot, Frédéric ,  Grandjean, Cyrille

IPC分类号： G01N33/569 ,  C07K16/12 ,  A61K47/48 ,  C07H3/06 ,  G01N33/563 ,  A61K39/112

CPC分类号： A61K39/0283 ,  A61K47/557 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/625 ,  C07H3/06 ,  C07K16/1228 ,  C07K2317/565 ,  C08B37/006 ,  G01N33/563 ,  G01N33/56916 ,  Y02A50/476

摘要： The present invention relates to a saccharide selected from the group consisting of:

        {B(E)CD}

        {(E)CDAB}n

        {AB(E)CD}n

Wherein A, B, C, E, D and n are as defined in claim 1. The invention also relates to derivatives thereof, pharmaceutical compositions comprising said derivatives, and kit for the diagnostic of Shigella flexneri type 2a infection comprising said derivatives.

摘要翻译： 本发明涉及一种选自以下的糖类：ƒ€ƒ€ƒ€ƒ€ƒ€ƒ{B（E）CD}€ƒ€ƒ€ƒ€ƒ€ƒ€ ƒ€ƒ{（E）CDAB} n€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ{AB（E）CD} n其中A，B，C，E，D和n如 本发明还涉及其衍生物，包含所述衍生物的药物组合物和用于诊断包括所述衍生物的福氏志贺氏菌2a型感染的试剂盒。

公开(公告)号：EP2150274A1

公开(公告)日：2010-02-10

申请号：EP08743288.6

申请日：2008-04-25

申请人： The United States Of America As Represented By The Secretary of the Army

发明人： VENKATESAN, Malabi M. ,  RANALLO, Ryan T. ,  BARNOY, Shoshana

IPC分类号： A61K39/02

CPC分类号： A61K39/0283 ,  A61K2039/522 ,  Y02A50/476

摘要： Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (&Dgr;senA, &Dgr;senB, &Dgr;virG, &Dgr;msbB2), WRSf2G15 (&Dgr;virG, &Dgr;setAB, &Dgr;senA, &Dgr;senB, &Dgr;msbB2), and WRSd5 (&Dgr;virG, &Dgr;stxAB, &Dgr;senA, &Dgr;senB, &Dgr;msbB2).